What's in Stendhal Americas, S.A.'s pipeline?

Stendhal Americas, S.A. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Stendhal Americas, S.A.'s portfolio?

Top competitors by shared drug class: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Heart Care Foundation, InVasc Therapeutics, Inc., Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/stendhal-americas-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Stendhal Americas, S.A. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stendhal Americas, S.A. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fimasartan; Hydrochlorothiazide	Fimasartan; Hydrochlorothiazide	phase 3	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (fimasartan); sodium-chloride cotransporter (hydrochlorothiazide)	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 shared drug class
Heart Care Foundation · 1 shared drug class
InVasc Therapeutics, Inc. · 1 shared drug class
Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stendhal Americas, S.A.:

Cite this brief

Drug Landscape (2026). Stendhal Americas, S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stendhal-americas-s-a. Accessed 2026-05-16.